Why the DIAMOND program milestone matters for Oculis Holding

Oculis Holding (NasdaqGM:OCS) reported that the final patients have completed study visits in both pivotal Phase 3 DIAMOND trials of OCS-01 for diabetic macular edema, moving the program toward key late stage readouts.

The company plans to share topline data from these registrational studies in June, with a potential new drug application submission targeted for the fourth quarter of 2026, subject to trial outcomes and regulatory review.

At a share price of $26.44, Oculis has a 1 month share price return of 7.09% and a year to date share price return of 32.20%. The 1 year total shareholder return of 55.53% points to building momentum compared with the flat 90 day share price move.

If this kind of late stage biotech catalyst interests you, it may be worth scanning for other potential opportunities through our screener of 33 healthcare AI stocks

With Oculis up 32.2% year to date and trading at $26.44 against an analyst target of about $48.06, the key question now is whether there is still an opportunity for investors or if the market is already pricing in expectations for the company.

Preferred price to book of 6.3x: Is it justified?

On a P/B basis, Oculis looks expensive, with a 6.3x multiple compared with a peer group at 3.5x and a broader US Pharmaceuticals average of 2.5x, even though the last close is $26.44.

P/B compares the market value of the company with its book value, which is essentially the net assets on the balance sheet. For a clinical stage biotech with limited current revenue and a net loss of $98.957 million, a higher P/B can reflect investor focus on the potential value of the pipeline rather than present earnings.

The current P/B level suggests the market is assigning a richer valuation to Oculis equity than to many peers, despite the company being unprofitable and forecast to remain unprofitable over the next 3 years. With Oculis trading above both the peer average P/B of 3.5x and the industry average of 2.5x, the share price embeds stronger expectations for future cash flows and successful execution than what is implied for many other US pharmaceutical names.

Result: Price-to-book of 6.3x (OVERVALUED)

However, the investment case still hinges on successful late stage trial readouts and eventual commercialization, while current revenue of US$1.199 million against a US$98.957 million loss highlights execution risk.

Another take: DCF suggests a very different picture

While the 6.3x P/B points to an expensive stock compared with peers, the SWS DCF model tells a contrasting story. With Oculis trading at $26.44 versus an estimated future cash flow value of $185.74, the DCF view screens the shares as deeply undervalued and raises a clear question: which signal do you trust more?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Oculis Holding for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 54 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on valuation and trial risk, sentiment is clearly divided. It makes sense to move quickly and examine the full picture yourself, starting with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock story. Use high quality screeners to spot ideas others might be missing.

• Hunt for value by focusing on companies that look mispriced on quality and fundamentals with the help of 54 high quality undervalued stocks.
• Prioritize resilience by concentrating on businesses with robust finances and low risk profiles using the 73 resilient stocks with low risk scores.
• Get ahead of the crowd by scanning a screener containing 25 high quality undiscovered gems before attention and liquidity potentially increase around them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.